Isomorphic Labs, the DeepMind spinout, applies AI-first drug design — built on AlphaFold and foundation models for biology — to discover medicines faster.
Isomorphic Labs is rethinking drug discovery from first principles as an AI-first science. Building on DeepMind’s breakthroughs in protein structure prediction, the company develops generative models that design molecules, predict interactions, and optimize candidates computationally before they enter a laboratory. Its partnership with pharmaceutical giants brings these capabilities to real therapeutic programs, pairing model development with medicinal-chemistry expertise. The company’s ambition is a future where designing a molecule for a target is a guided computational process measured in weeks rather than years, with laboratory work focused on validation instead of exploration. Though still early, its combination of world-class model research and industry partnerships makes it the most watched entrant in AI-driven drug design. Isomorphic’s approach treats biology as a design space where structure, function, and drug-like properties can be modeled jointly — a departure from screening libraries and hoping for hits. The company continues to invest in the underlying modeling science, publishing research that advances the field while building proprietary capabilities designed for therapeutic design at scale.
Isomorphic Labs collaborates through partnership agreements with pharmaceutical companies rather than selling software. Commercial terms combine upfront commitments, research funding, and milestones tied to program progress.
Pharmaceutical companies seeking AI-native drug design partnerships, and computational biology researchers who want to work at the frontier of structure-based generative design. It attracts organizations that see AI as a reorganization of discovery itself rather than an incremental tool layered onto legacy screening processes.